Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan vs Atenolol/HCTZ on Microcirculation in Hypertension
NCT00396656Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2005
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of valsartan in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoint: Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected Sites at Week 43. Started Dec 2005; status: completed.
02
Drugs
valsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00396656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396656.